More recently, we have developed an ADP2-based ADAM8 IHC assay, which confirmed the ADAM8 expression rate in TNBC (36.11% = 22/61 samples) and expanded ADAM8 positivity to all breast cancers, i.e., 33.9% (166 of 490 samples) of breast tumors of any subtype were ADAM8+ [7]. Here, ADAM8 is linked to breast cancer.